Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491641 | 1.00 | LPAR3 (0.48) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2494369 | 1.00 | LPAR3 (0.48) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2490786 | 0.95 | LPAR3 (0.44) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2494184 | 0.95 | LPAR3 (0.44) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2498916 | 0.93 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL12191704 | 0.89 | LPAR3 (0.40) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2493025 | 0.88 | CYP3A4 (0.44) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL2493153 | 0.88 | CYP3A4 (0.44) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL12191706 | 0.86 | LPAR3 (0.40) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL12191705 | 0.82 | CYP3A4 (0.39) | LPAR3LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882694-B1 | OLIGOMERS AND POLYMERS OF THIOPHENE COMPOUNDS HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL IND LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8030438-B2 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1882694-A1 | THIOPHENE COMPOUND HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | RRP12, NR2E1, TST | LPAR3 3232/4885LPAR2 3776/4885LPAR1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.